SCHEMBL5486246

SCHEMBL5486246

CC(C)(C)NC(=O)Oc1ccc(-c2ccccc2)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
ACLY P53396 9/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ESR2 Q92731 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
POLB P06746 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
ACACB O00763 1/20 0.40
ACACA Q13085 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27529112 0.83 MAPT (0.45) NPC1LMNAMAPTCASP3SENP8
SCHEMBL27502700 0.80 ABCB1 (0.53) NPC1LMNAMAPTCASP3SENP8
SCHEMBL27960497 0.77 ALDH1A1 (0.50) NPC1MAPTMEN1KMT2ACYP1A2
SCHEMBL27499442 0.76 FGFR1 (0.37) NPC1LMNAMAPTCASP3SENP8
SCHEMBL27520757 0.76 CLCN2 (0.38) NPC1LMNAMAPTCASP3SENP8
SCHEMBL7571353 0.73 CYP1A2 (0.46) MAPTESR2CYP1A2CYP2C19
SCHEMBL6989070 0.73 LMNA (0.43) NPC1LMNAMAPTCASP3SENP8
SCHEMBL3863548 0.72 ESR2 (0.45) LMNAACLYMEN1KMT2AESR2
SCHEMBL27520753 0.71 LMNA (0.38) NPC1LMNAMAPTCASP3SENP8
SCHEMBL27698905 0.71 MAPK1 (0.44) LMNAMAPTMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010283-A1 MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-01-12 US disclosed
US-20120010283-A1 MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-01-12 US disclosed
US-8003693-B2 Modulation of anxiety through blockade of anandamide hydrolysis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-08-23 US disclosed
US-8003693-B2 Modulation of anxiety through blockade of anandamide hydrolysis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-08-23 US disclosed
US-20090048337-A1 Modulation of anxiety through blockade of anandamide hydrolysis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-02-19 US disclosed
US-20090048337-A1 Modulation of anxiety through blockade of anandamide hydrolysis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-02-19 US disclosed
US-7176201-B2 Modulation of anxiety through blockade of anandamide hydrolysis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-02-13 US disclosed
US-7176201-B2 Modulation of anxiety through blockade of anandamide hydrolysis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-02-13 US disclosed
US-7176201-B2 Modulation of anxiety through blockade of anandamide hydrolysis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048337-A1 Modulation of anxiety through blockade of anandamide hydrolysis FAAH, FAAH2, CNR2 NPC1 625/4885LMNA 1522/4885MAPT 3209/4885
US-20120010283-A1 MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS FAAH, FAAH2, CNR2 NPC1 727/4885LMNA 1697/4885MAPT 3136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.